Study of CUG252 in Healthy Volunteers and in Patients With Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The intent of this study is to evaluate the safety and tolerability of single escalating
subcutaneous doses of CUG252 in healthy adult subjects, and multiple escalating subcutaneous
doses of CUG252 in patients with mild to moderate Systemic Lupus Erythematosus (SLE)